Login to Your Account

Cancer-focused Neovia advances first candidate into a phase I trial

By Michael Fitzhugh
Staff Writer

Wednesday, January 25, 2017

Neovia Oncology Ltd. has enrolled its first patient into a phase I dose-escalation study of intravenous NEV-801, a combination of the natural products podofilox and camptothecin that inhibits topoisomerase I and II.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription